BRIEF-Teva Confirms Efficacy, Safety Of AJOVY For Prevention Of Migraine With Results From Phase 3 Trial In China

Reuters04-11

April 11 (Reuters) - Teva Pharmaceutical Industries Ltd

* TEVA CONFIRMS EFFICACY AND SAFETY OF AJOVY® (FREMANEZUMAB) FOR THE PREVENTION OF MIGRAINE WITH RESULTS FROM PHASE 3 TRIAL IN CHINA

* TEVA: AJOVY CONFIRMED A FAVORABLE SAFETY PROFILE

* TEVA: ALL CRITICAL EFFICACY ENDPOINTS MET SIGNIFICANCE AS SET OUT APRIORI THROUGH HIERARCHICAL TESTING

* TEVA: AJOVY CONFIRMS EFFICACY IN NEW PHASE 3 DATA SIGNIFICANTLY REDUCING NUMBER OF MIGRAINE DAYS PER MONTH

* TEVA: * ALL CRITICAL EFFICACY ENDPOINTS MET SIGNIFICANCE AS SET OUT APRIORI THROUGH HIERARCHICAL TESTING

* TEVA: AJOVY CONFIRMED A FAVORABLE SAFETY PROFILE

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2426526667?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-11 22:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2426526667","market":"us","top_or_hot":-1,"title":"BRIEF-Teva Confirms Efficacy, Safety Of AJOVY For Prevention Of Migraine With Results From Phase 3 Trial In China","media":"Reuters","content":"<html><body><p>April 11 (Reuters) - Teva Pharmaceutical Industries Ltd</p><p> :</p><p>   * TEVA CONFIRMS EFFICACY AND SAFETY OF AJOVY® (FREMANEZUMAB) FOR THE PREVENTION OF MIGRAINE WITH RESULTS FROM PHASE 3 TRIAL IN CHINA</p><p>   * TEVA: AJOVY CONFIRMED A FAVORABLE SAFETY PROFILE</p><p>   * TEVA: ALL CRITICAL EFFICACY ENDPOINTS MET SIGNIFICANCE AS SET OUT APRIORI THROUGH HIERARCHICAL TESTING</p><p>   * TEVA: AJOVY CONFIRMS EFFICACY IN NEW PHASE 3 DATA SIGNIFICANTLY REDUCING NUMBER OF MIGRAINE DAYS PER MONTH</p><p>   * TEVA: * ALL CRITICAL EFFICACY ENDPOINTS MET SIGNIFICANCE AS SET OUT APRIORI THROUGH HIERARCHICAL TESTING</p><p>   * TEVA: AJOVY CONFIRMED A FAVORABLE SAFETY PROFILE</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Teva Confirms Efficacy, Safety Of AJOVY For Prevention Of Migraine With Results From Phase 3 Trial In China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Teva Confirms Efficacy, Safety Of AJOVY For Prevention Of Migraine With Results From Phase 3 Trial In China\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-11 22:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>April 11 (Reuters) - Teva Pharmaceutical Industries Ltd :   * TEVA CONFIRMS EFFICACY AND SAFETY OF AJOVY® (FREMANEZUMAB) FOR THE PREVENTION OF MIGRAINE WITH RESULTS FROM PHASE 3 TRIAL IN CHINA   * ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2426526667","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2426526667","pubTimestamp":1712846474,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 11  - Teva Pharmaceutical Industries Ltd :   * TEVA CONFIRMS EFFICACY AND SAFETY OF AJOVY  FOR THE PREVENTION OF MIGRAINE WITH RESULTS FROM PHASE 3 TRIAL IN CHINA   * TEVA: AJOVY CONFIRMED A FAVORABLE SAFETY PROFILE   * TEVA: ALL CRITICAL EFFICACY ENDPOINTS MET SIGNIFICANCE AS SET OUT APRIORI THROUGH HIERARCHICAL TESTING   * TEVA: AJOVY CONFIRMS EFFICACY IN NEW PHASE 3 DATA SIGNIFICANTLY REDUCING NUMBER OF MIGRAINE DAYS PER MONTH   * TEVA: * ALL CRITICAL EFFICACY ENDPOINTS MET SIGNIFICANCE AS SET OUT APRIORI THROUGH HIERARCHICAL TESTING   * TEVA: AJOVY CONFIRMED A FAVORABLE SAFETY PROFILESource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4559":"巴菲特持仓","BK4588":"碎股","BK4007":"制药","BK4584":"避孕概念","BK4566":"资本集团","TEVA":"梯瓦制药","BK4557":"大麻股"},"translate_title":"简报——Teva证实AJOVY预防偏头痛的有效性和安全性，并在中国进行3期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":0.9},"content_text":"April 11 (Reuters) - Teva Pharmaceutical Industries Ltd :   * TEVA CONFIRMS EFFICACY AND SAFETY OF AJOVY® (FREMANEZUMAB) FOR THE PREVENTION OF MIGRAINE WITH RESULTS FROM PHASE 3 TRIAL IN CHINA   * TEVA: AJOVY CONFIRMED A FAVORABLE SAFETY PROFILE   * TEVA: ALL CRITICAL EFFICACY ENDPOINTS MET SIGNIFICANCE AS SET OUT APRIORI THROUGH HIERARCHICAL TESTING   * TEVA: AJOVY CONFIRMS EFFICACY IN NEW PHASE 3 DATA SIGNIFICANTLY REDUCING NUMBER OF MIGRAINE DAYS PER MONTH   * TEVA: * ALL CRITICAL EFFICACY ENDPOINTS MET SIGNIFICANCE AS SET OUT APRIORI THROUGH HIERARCHICAL TESTING   * TEVA: AJOVY CONFIRMED A FAVORABLE SAFETY PROFILESource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2426526667"}